1	Tumor	tumor	_	_	_	_	_	_	_
2	necrosis	necrosis	_	_	_	_	_	_	_
3	factor	factor	_	_	_	_	_	_	_
4	alpha	alpha	_	_	_	_	_	_	_
5	decreases	decrease	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	and	and	_	_	_	_	_	_	_
8	interleukin-10	interleukin-10	_	_	_	_	_	_	_
9	increases	increase	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	sensitivity	sensitivity	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	human	human	_	_	_	_	_	_	_
15	monocytes	monocyte	_	_	_	_	_	_	_
16	to	to	_	_	_	_	_	_	_
17	dexamethasone	dexamethasone	_	_	_	_	_	_	_
18	:	:	_	_	_	_	_	_	_
19	potential	potential	_	_	_	_	_	_	_
20	regulation	regulation	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	the	the	_	_	_	_	_	_	_
23	glucocorticoid	glucocorticoid	_	_	_	_	_	_	_
24	receptor	receptor	_	_	_	_	_	_	_
25	.	.	_	_	_	_	_	_	_

1	Resistance	resistance	_	_	_	_	_	_	_
2	to	to	_	_	_	_	_	_	_
3	glucocorticoid	glucocorticoid	_	_	_	_	_	_	_
4	therapy	therapy	_	_	_	_	_	_	_
5	has	have	_	_	_	_	_	_	_
6	been	be	_	_	_	_	_	_	_
7	observed	observe	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	patients	patient	_	_	_	_	_	_	_
10	with	with	_	_	_	_	_	_	_
11	autoimmune/inflammatory	autoimmune/inflammatory	_	_	_	_	_	_	_
12	diseases	disease	_	_	_	_	_	_	_
13	and	and	_	_	_	_	_	_	_
14	may	may	_	_	_	_	_	_	_
15	be	be	_	_	_	_	_	_	_
16	related	related	_	_	_	_	_	_	_
17	to	to	_	_	_	_	_	_	_
18	the	the	_	_	_	_	_	_	_
19	inflammatory	inflammatory	_	_	_	_	_	_	_
20	process	process	_	_	_	_	_	_	_
21	itself	itself	_	_	_	_	_	_	_
22	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	aim	aim	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	this	this	_	_	_	_	_	_	_
5	study	study	_	_	_	_	_	_	_
6	was	be	_	_	_	_	_	_	_
7	to	to	_	_	_	_	_	_	_
8	examine	examine	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	ability	ability	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	tumor	tumor	_	_	_	_	_	_	_
13	necrosis	necrosis	_	_	_	_	_	_	_
14	factor	factor	_	_	_	_	_	_	_
15	alpha	alpha	_	_	_	_	_	_	_
16	(	(	_	_	_	_	_	_	_
17	TNFalpha	TNFalpha	_	_	_	_	_	_	_
18	,	,	_	_	_	_	_	_	_
19	a	a	_	_	_	_	_	_	_
20	proinflammatory	proinflammatory	_	_	_	_	_	_	_
21	cytokine	cytokine	_	_	_	_	_	_	_
22	)	)	_	_	_	_	_	_	_
23	and	and	_	_	_	_	_	_	_
24	interleukin	interleukin	_	_	_	_	_	_	_
25	(	(	_	_	_	_	_	_	_
26	IL)-10	IL)-10	_	_	_	_	_	_	_
27	(	(	_	_	_	_	_	_	_
28	an	an	_	_	_	_	_	_	_
29	anti-inflammatory	anti-inflammatory	_	_	_	_	_	_	_
30	cytokine	cytokine	_	_	_	_	_	_	_
31	)	)	_	_	_	_	_	_	_
32	to	to	_	_	_	_	_	_	_
33	differentially	differentially	_	_	_	_	_	_	_
34	regulate	regulate	_	_	_	_	_	_	_
35	the	the	_	_	_	_	_	_	_
36	sensitivity	sensitivity	_	_	_	_	_	_	_
37	of	of	_	_	_	_	_	_	_
38	human	human	_	_	_	_	_	_	_
39	monocytes/macrophages	monocytes/macrophage	_	_	_	_	_	_	_
40	to	to	_	_	_	_	_	_	_
41	glucocorticoids	glucocorticoid	_	_	_	_	_	_	_
42	.	.	_	_	_	_	_	_	_

1	To	to	_	_	_	_	_	_	_
2	accomplish	accomplish	_	_	_	_	_	_	_
3	this	this	_	_	_	_	_	_	_
4	,	,	_	_	_	_	_	_	_
5	we	we	_	_	_	_	_	_	_
6	first	first	_	_	_	_	_	_	_
7	analyzed	analyze	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	pattern	pattern	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	TNFalpha	TNFalpha	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	IL-10	IL-10	_	_	_	_	_	_	_
14	inhibition	inhibition	_	_	_	_	_	_	_
15	by	by	_	_	_	_	_	_	_
16	dexamethasone	dexamethasone	_	_	_	_	_	_	_
17	in	in	_	_	_	_	_	_	_
18	LPS-stimulated	lps-stimulated	_	_	_	_	_	_	_
19	whole-blood	whole-blood	_	_	_	_	_	_	_
20	cell	cell	_	_	_	_	_	_	_
21	cultures	culture	_	_	_	_	_	_	_
22	.	.	_	_	_	_	_	_	_

1	Second	second	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	we	we	_	_	_	_	_	_	_
4	studied	study	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	modulation	modulation	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	sensitivity	sensitivity	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	these	these	_	_	_	_	_	_	_
12	cells	cell	_	_	_	_	_	_	_
13	to	to	_	_	_	_	_	_	_
14	dexamethasone	dexamethasone	_	_	_	_	_	_	_
15	by	by	_	_	_	_	_	_	_
16	preincubation	preincubation	_	_	_	_	_	_	_
17	with	with	_	_	_	_	_	_	_
18	TNFalpha	TNFalpha	_	_	_	_	_	_	_
19	or	or	_	_	_	_	_	_	_
20	IL-10	IL-10	_	_	_	_	_	_	_
21	and	and	_	_	_	_	_	_	_
22	measurement	measurement	_	_	_	_	_	_	_
23	of	of	_	_	_	_	_	_	_
24	LPS-stimulated	lps-stimulated	_	_	_	_	_	_	_
25	IL-6	il-6	_	_	_	_	_	_	_
26	secretion	secretion	_	_	_	_	_	_	_
27	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	addition	addition	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	we	we	_	_	_	_	_	_	_
5	evaluated	evaluate	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	effect	effect	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	dexamethasone	dexamethasone	_	_	_	_	_	_	_
10	on	on	_	_	_	_	_	_	_
11	phorbolmyristate-acetate-stimulated	phorbolmyristate-acetate-stimulated	_	_	_	_	_	_	_
12	IL-1	il-1	_	_	_	_	_	_	_
13	receptor	receptor	_	_	_	_	_	_	_
14	antagonist	antagonist	_	_	_	_	_	_	_
15	secretion	secretion	_	_	_	_	_	_	_
16	by	by	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	human	human	_	_	_	_	_	_	_
19	monocytic	monocytic	_	_	_	_	_	_	_
20	cell	cell	_	_	_	_	_	_	_
21	line	line	_	_	_	_	_	_	_
22	U937	u937	_	_	_	_	_	_	_
23	.	.	_	_	_	_	_	_	_

1	Finally	finally	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	we	we	_	_	_	_	_	_	_
4	investigated	investigate	_	_	_	_	_	_	_
5	whether	whether	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	modulation	modulation	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	corticosensitivity	corticosensitivity	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	TNFalpha-	tnfalpha-	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	IL-10-pretreated	il-10-pretreated	_	_	_	_	_	_	_
14	U937	u937	_	_	_	_	_	_	_
15	cells	cell	_	_	_	_	_	_	_
16	was	be	_	_	_	_	_	_	_
17	related	relate	_	_	_	_	_	_	_
18	to	to	_	_	_	_	_	_	_
19	a	a	_	_	_	_	_	_	_
20	change	change	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	the	the	_	_	_	_	_	_	_
23	glucocorticoid	glucocorticoid	_	_	_	_	_	_	_
24	receptor	receptor	_	_	_	_	_	_	_
25	concentration	concentration	_	_	_	_	_	_	_
26	and	and	_	_	_	_	_	_	_
27	affinity	affinity	_	_	_	_	_	_	_
28	.	.	_	_	_	_	_	_	_

1	Dexamethasone	Dexamethasone	_	_	_	_	_	_	_
2	had	have	_	_	_	_	_	_	_
3	different	different	_	_	_	_	_	_	_
4	effects	effect	_	_	_	_	_	_	_
5	on	on	_	_	_	_	_	_	_
6	LPS-induced	lps-induced	_	_	_	_	_	_	_
7	TNFalpha	TNFalpha	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	IL-10	IL-10	_	_	_	_	_	_	_
10	secretion	secretion	_	_	_	_	_	_	_
11	;	;	_	_	_	_	_	_	_
12	whereas	whereas	_	_	_	_	_	_	_
13	it	it	_	_	_	_	_	_	_
14	suppressed	suppress	_	_	_	_	_	_	_
15	TNFalpha	TNFalpha	_	_	_	_	_	_	_
16	in	in	_	_	_	_	_	_	_
17	a	a	_	_	_	_	_	_	_
18	dose-dependent	dose-dependent	_	_	_	_	_	_	_
19	fashion	fashion	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	its	its	_	_	_	_	_	_	_
22	effect	effect	_	_	_	_	_	_	_
23	on	on	_	_	_	_	_	_	_
24	IL-10	IL-10	_	_	_	_	_	_	_
25	secretion	secretion	_	_	_	_	_	_	_
26	was	be	_	_	_	_	_	_	_
27	biphasic	biphasic	_	_	_	_	_	_	_
28	,	,	_	_	_	_	_	_	_
29	producing	produce	_	_	_	_	_	_	_
30	stimulation	stimulation	_	_	_	_	_	_	_
31	at	at	_	_	_	_	_	_	_
32	lower	low	_	_	_	_	_	_	_
33	,	,	_	_	_	_	_	_	_
34	and	and	_	_	_	_	_	_	_
35	inhibition	inhibition	_	_	_	_	_	_	_
36	at	at	_	_	_	_	_	_	_
37	higher	high	_	_	_	_	_	_	_
38	doses	dose	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	concentration	concentration	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	LPS	lps	_	_	_	_	_	_	_
5	employed	employ	_	_	_	_	_	_	_
6	influenced	influence	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	effect	effect	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	dexamethasone	dexamethasone	_	_	_	_	_	_	_
11	on	on	_	_	_	_	_	_	_
12	IL-10	IL-10	_	_	_	_	_	_	_
13	secretion	secretion	_	_	_	_	_	_	_
14	(	(	_	_	_	_	_	_	_
15	P	p	_	_	_	_	_	_	_
16	<	<	_	_	_	_	_	_	_
17	0.001	0.001	_	_	_	_	_	_	_
18	)	)	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	Pretreatment	Pretreatment	_	_	_	_	_	_	_
2	with	with	_	_	_	_	_	_	_
3	TNFalpha	TNFalpha	_	_	_	_	_	_	_
4	diminished	diminish	_	_	_	_	_	_	_
5	,	,	_	_	_	_	_	_	_
6	and	and	_	_	_	_	_	_	_
7	with	with	_	_	_	_	_	_	_
8	IL-10	IL-10	_	_	_	_	_	_	_
9	improved	improve	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	ability	ability	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	dexamethasone	dexamethasone	_	_	_	_	_	_	_
15	to	to	_	_	_	_	_	_	_
16	suppress	suppress	_	_	_	_	_	_	_
17	IL-6	il-6	_	_	_	_	_	_	_
18	secretion	secretion	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	whole-blood	whole-blood	_	_	_	_	_	_	_
21	cell	cell	_	_	_	_	_	_	_
22	cultures	culture	_	_	_	_	_	_	_
23	(	(	_	_	_	_	_	_	_
24	P	p	_	_	_	_	_	_	_
25	<	<	_	_	_	_	_	_	_
26	0.01	0.01	_	_	_	_	_	_	_
27	for	for	_	_	_	_	_	_	_
28	both	both	_	_	_	_	_	_	_
29	)	)	_	_	_	_	_	_	_
30	and	and	_	_	_	_	_	_	_
31	to	to	_	_	_	_	_	_	_
32	enhance	enhance	_	_	_	_	_	_	_
33	IL-1	il-1	_	_	_	_	_	_	_
34	receptor	receptor	_	_	_	_	_	_	_
35	antagonist	antagonist	_	_	_	_	_	_	_
36	secretion	secretion	_	_	_	_	_	_	_
37	by	by	_	_	_	_	_	_	_
38	U937	u937	_	_	_	_	_	_	_
39	cells	cell	_	_	_	_	_	_	_
40	(	(	_	_	_	_	_	_	_
41	P	p	_	_	_	_	_	_	_
42	<	<	_	_	_	_	_	_	_
43	0.05	0.05	_	_	_	_	_	_	_
44	for	for	_	_	_	_	_	_	_
45	both	both	_	_	_	_	_	_	_
46	)	)	_	_	_	_	_	_	_
47	.	.	_	_	_	_	_	_	_

1	TNFalpha	TNFalpha	_	_	_	_	_	_	_
2	decreased	decrease	_	_	_	_	_	_	_
3	(	(	_	_	_	_	_	_	_
4	P	p	_	_	_	_	_	_	_
5	<	<	_	_	_	_	_	_	_
6	0.001	0.001	_	_	_	_	_	_	_
7	)	)	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	while	while	_	_	_	_	_	_	_
10	IL-10	IL-10	_	_	_	_	_	_	_
11	increased	increase	_	_	_	_	_	_	_
12	(	(	_	_	_	_	_	_	_
13	P	p	_	_	_	_	_	_	_
14	<	<	_	_	_	_	_	_	_
15	0.001	0.001	_	_	_	_	_	_	_
16	)	)	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	the	the	_	_	_	_	_	_	_
19	concentration	concentration	_	_	_	_	_	_	_
20	of	of	_	_	_	_	_	_	_
21	dexamethasone	dexamethasone	_	_	_	_	_	_	_
22	binding	binding	_	_	_	_	_	_	_
23	sites	site	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	these	these	_	_	_	_	_	_	_
26	cells	cell	_	_	_	_	_	_	_
27	,	,	_	_	_	_	_	_	_
28	with	with	_	_	_	_	_	_	_
29	no	no	_	_	_	_	_	_	_
30	discernible	discernible	_	_	_	_	_	_	_
31	effect	effect	_	_	_	_	_	_	_
32	on	on	_	_	_	_	_	_	_
33	their	their	_	_	_	_	_	_	_
34	binding	binding	_	_	_	_	_	_	_
35	affinity	affinity	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	conclude	conclude	_	_	_	_	_	_	_
3	that	that	_	_	_	_	_	_	_
4	glucocorticoids	glucocorticoid	_	_	_	_	_	_	_
5	differentially	differentially	_	_	_	_	_	_	_
6	modulate	modulate	_	_	_	_	_	_	_
7	TNFalpha	TNFalpha	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	IL-10	IL-10	_	_	_	_	_	_	_
10	secretion	secretion	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	human	human	_	_	_	_	_	_	_
13	monocytes	monocyte	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	a	a	_	_	_	_	_	_	_
16	LPS	LPS	_	_	_	_	_	_	_
17	dose-dependent	dose-dependent	_	_	_	_	_	_	_
18	fashion	fashion	_	_	_	_	_	_	_
19	and	and	_	_	_	_	_	_	_
20	that	that	_	_	_	_	_	_	_
21	the	the	_	_	_	_	_	_	_
22	sensitivity	sensitivity	_	_	_	_	_	_	_
23	of	of	_	_	_	_	_	_	_
24	these	these	_	_	_	_	_	_	_
25	cells	cell	_	_	_	_	_	_	_
26	to	to	_	_	_	_	_	_	_
27	glucocorticoids	glucocorticoid	_	_	_	_	_	_	_
28	is	be	_	_	_	_	_	_	_
29	altered	alter	_	_	_	_	_	_	_
30	by	by	_	_	_	_	_	_	_
31	TNFalpha	TNFalpha	_	_	_	_	_	_	_
32	or	or	_	_	_	_	_	_	_
33	IL-10	IL-10	_	_	_	_	_	_	_
34	pretreatment	pretreatment	_	_	_	_	_	_	_
35	;	;	_	_	_	_	_	_	_
36	TNFalpha	TNFalpha	_	_	_	_	_	_	_
37	blocks	block	_	_	_	_	_	_	_
38	their	their	_	_	_	_	_	_	_
39	effects	effect	_	_	_	_	_	_	_
40	,	,	_	_	_	_	_	_	_
41	whereas	whereas	_	_	_	_	_	_	_
42	IL-10	IL-10	_	_	_	_	_	_	_
43	acts	act	_	_	_	_	_	_	_
44	synergistically	synergistically	_	_	_	_	_	_	_
45	with	with	_	_	_	_	_	_	_
46	glucocorticoids	glucocorticoid	_	_	_	_	_	_	_
47	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	is	be	_	_	_	_	_	_	_
3	accompanied	accompany	_	_	_	_	_	_	_
4	by	by	_	_	_	_	_	_	_
5	opposite	opposite	_	_	_	_	_	_	_
6	glucocorticoid	glucocorticoid	_	_	_	_	_	_	_
7	receptor	receptor	_	_	_	_	_	_	_
8	changes	change	_	_	_	_	_	_	_
9	,	,	_	_	_	_	_	_	_
10	respectively	respectively	_	_	_	_	_	_	_
11	opposing	oppose	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	favoring	favor	_	_	_	_	_	_	_
14	glucocorticoid	glucocorticoid	_	_	_	_	_	_	_
15	actions	action	_	_	_	_	_	_	_
16	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	study	study	_	_	_	_	_	_	_
3	suggests	suggest	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	pattern	pattern	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	pro-/antiinflammatory	pro-/antiinflammatory	_	_	_	_	_	_	_
9	cytokine	cytokine	_	_	_	_	_	_	_
10	secretion	secretion	_	_	_	_	_	_	_
11	may	may	_	_	_	_	_	_	_
12	alter	alter	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	response	response	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	patients	patient	_	_	_	_	_	_	_
17	to	to	_	_	_	_	_	_	_
18	glucocorticoid	glucocorticoid	_	_	_	_	_	_	_
19	therapy	therapy	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

